# Michael T. Tetzlaff

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-t-tetzlaff/

## Facts

| Field | Value |
| --- | --- |
| Citations | 24,874 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 64 |
| i10-index | 213 |
| OpenAlex ID | https://openalex.org/A5067831105 |
| ORCID iD | https://orcid.org/0000-0001-7899-4138 |
| Works | 799 |

## Researcher papers

- [Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy](https://scholariq.org/papers/loss-of-pten-promotes-resistance-to-t-cell-mediated-immunotherapy/)
- [Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma](https://scholariq.org/papers/neoadjuvant-immune-checkpoint-blockade-in-high-risk-resectable-melanoma/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immune cells in cancer](https://scholariq.org/topics/immune-cells-in-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.